9 results about "Polymersome" patented technology

The present invention relates to nanoparticles or microparticles for binding to cell surfaces, said nanoparticles or microparticles comprising (i) a plurality of different ligand species on their outer surface capable of binding to different receptor species on the cell surface, and (ii) polymer brushes on their outer surface. The present invention further relates to pharmaceutical compositions comprising a plurality of nanoparticles or microparticles of the invention, medical uses of such nanoparticles or microparticles, and vaccines comprising such nanoparticles or microparticles.

Described herein are compositions that are suitable for use in analyte sensing in biological samples and in medical diagnostics. The compositions include an oxidase capable of oxidizing the analyte of interest to produce hydrogen peroxide, a peroxidase, and a chemical compound, such as a near-infrared fluorescent compound, that is a substrate for the peroxidase. The oxidase, the peroxidase, and the chemical compound are encapsulated by vesicle that includes a lipid or polymeric bilayer, such as liposome and polymersome. The peroxidase catalyzes the oxidation of the chemical compound by hydrogen peroxide. Methods of analyte sensing in biological samples using these compositions, and methods of preparing the compositions are also described.

The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. The exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.

The present invention relates to polymersomes comprising copolymers of poly(ethylene glycol) (PEG) and poly(lactic acid) (PLA) or poly(oligo(ethylene glycol) methyl ether methacrylate) (POEGMA) and PLA which have both enhanced stability and a narrow polydispersity. Specifically, the present invention is directed to polymersomes comprising PEG-PLA or POEGMA-PLA copolymers in which the PEG block has a weight-average molecular weight of from 1,500 to 2,500 Da or the POEGMA block has a weight-average molecular weight of from 1,500 to 5,000 Da (preferably from 1,500 to 3,000 Da), and the PLA block has a weight-average molecular weight of from 7,500 to 14,000 Da, and the polydispersity index of the polymersome is less than 0.15 as measured by dynamic light scattering. The present invention further relates to a specific solvent injection method for preparing such polymersomes, which imparts low polydispersity on the polymersomes. Specifically, this method comprises dissolving the PEG-PLA or POEGMA-PLA copolymers in an organic solvent having a polarity index of greater than 5.0 and then adding the resulting organic polymer solution to an aqueous solvent. The present invention is further directed to pharmaceutical compositions comprising such polymersomes, to uses of such polymersomes and pharmaceutical compositions in medicine, and to vaccines comprising such polymersomes.

The present invention provides polymersomes comprising amphiphilic block-copolymers and their use to quantify ammonia in samples (e.g., body fluid samples). More particularly, it provides a polymersome comprising (a) a membrane, which comprises a block copolymer of poly(styrene) (PS) and poly(ethylene oxide) (PEO), wherein the PS / PEO molecular weight ratio is higher than 1.0 and lower than 4.0; and (b) a core which encloses an acid and at least one pH-sensitive dye. Compositions, strips and kits comprising the polymersomes are also provided along with methods of quantifying ammonia in a sample using the polymersomes, compositions and kit.

The present invention relates to polymersomes which have enhanced stability, and copolymer materials that are suitable for making such polymersomes. The polymersomes comprise a particular type of triblock copolymer which, under typical in vivo physiological conditions, is resistant to hydrolysis and which therefore allows the polymersomes to maintain a constant electrostatic potential (zeta potential) for a longer period of time. This allows for improved targeting of polymersomes to their site of action in vivo. Specifically, the present invention is directed to a triblock copolymer comprising a hydrophilic block, a linker moiety and a hydrophobic block, wherein the rate of hydrolysis of the linker moiety is lower under typical in vivo physiological conditions that the rate of hydrolysis of the hydrophobic block. The present invention is further directed to polymersomes comprising such a triblock copolymer, as well as pharmaceutical compositions comprising a plurality of such polymersomes and one or more pharmaceutically acceptable excipients or diluents. The present invention is further directed to uses of such polymersomes and pharmaceutical compositions in medicine, and to vaccines comprising such polymersomes.

Methotrexate-containing polymersomes and methods for treating ectopic pregnancy or for treating gestational choriocarcinoma using the methotrexate-containing polymersomes.

The present application relates to pH-sensitive polymersomes. The polymersomes are capable of degradation at endosomes' mild acidic pH into resorbable materials, which also allows avoiding liposome premature degradation of the payload once internalised inside the cells. The polymersomes can thus be used in methods for the treatment or prevention of diseases.

The present disclosure relates to copolymers and polymersomes for targeted delivery of biomolecules to living organisms. Exemplary copolymers include an initiator block, a propagator block, and a linker connecting the initiator block and the propagator block. The initiator block includes a glycan head configured to provide targeted delivery, and the propagator block includes a functional moiety configured to provide desired properties to the polymersome.